Liquid biopsy in ovarian cancer in China and the world: current status and future perspectives

被引:1
作者
Zhang, Hui [1 ]
Wang, Lingxia [2 ]
Wu, Huanwen [1 ]
机构
[1] Chinese Acad Med Sci & Peking Union Med Coll Hosp, Peking Union Med Coll, Dept Pathol, Beijing, Peoples R China
[2] MSD China, MRL Global Med Affairs, Shanghai, Peoples R China
来源
FRONTIERS IN ONCOLOGY | 2023年 / 13卷
关键词
ovarian cancer; liquid biopsy; circulating tumor DNA; cell-free DNA; poly(ADP)ribose polymerase inhibitors; China; CIRCULATING TUMOR-CELLS; UK COLLABORATIVE TRIAL; NEOADJUVANT CHEMOTHERAPY; PROGNOSTIC-SIGNIFICANCE; PROMOTER METHYLATION; REVERSION MUTATIONS; PERIPHERAL-BLOOD; PREDICTIVE-VALUE; UNITED-STATES; FREE DNA;
D O I
10.3389/fonc.2023.1276085
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Ovarian cancer (OC) is the eighth most common cancer in women, but the mild, non-specific clinical presentation in early stages often prevents diagnosis until progression to advanced-stage disease, contributing to the high mortality associated with OC. While serum cancer antigen 125 (CA-125) has been successfully used as a blood-borne marker and is routinely monitored in patients with OC, CA-125 testing has limitations in sensitivity and specificity and does not provide direct information on important molecular characteristics that can guide treatment decisions, such as homologous recombination repair deficiency. We comprehensively review the literature surrounding methods based on liquid biopsies, which may provide improvements in sensitivity, specificity, and provide valuable additional information to enable early diagnosis, monitoring of recurrence/progression/therapeutic response, and accurate prognostication for patients with OC, highlighting applications of this research in China.
引用
收藏
页数:17
相关论文
共 129 条
[1]   Molecular Profiling and Prognostic Relevance of Circulating Tumor Cells in the Blood of Ovarian Cancer Patients at Primary Diagnosis and After Platinum-Based Chemotherapy [J].
Aktas, Bahriye ;
Kasimir-Bauer, Sabine ;
Heubner, Martin ;
Kimmig, Rainer ;
Wimberger, Pauline .
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2011, 21 (05) :822-830
[2]  
Alves Mariana Cartaxo, 2020, Tumour Biol, V42, p1010428320919198, DOI 10.1177/1010428320919198
[3]  
[Anonymous], 2023, Clinical practice guidelines in oncology. Non small cell lung cancer
[4]  
[Anonymous], 2022, EPARAssessment ReportVariation (Zejula-H-C-003943-II-0019EMA/531223/2020)
[5]  
[Anonymous], 2020, Zai Lab Announces NMPA Approval of ZEJULA (Niraparib) for First-Line Maintenance Treatment of Ovarian Cancer in CHINA
[6]   Molecular Response to Neoadjuvant Chemotherapy in High-Grade Serous Ovarian Carcinoma [J].
Arend, Rebecca C. ;
Londono, Angelina I. ;
Montgomery, Allison M. ;
Smith, Haller J. ;
Dobbin, Zachary C. ;
Katre, Ashwini A. ;
Martinez, Alba ;
Yang, Eddy S. ;
Alvarez, Ronald D. ;
Huh, Warner K. ;
Bevis, Kerri S. ;
Straughn, J. Michael, Jr. ;
Estes, Jacob M. ;
Novak, Lea ;
Crossman, David K. ;
Cooper, Sara J. ;
Landen, Charles N. ;
Leath, Charles A., III .
MOLECULAR CANCER RESEARCH, 2018, 16 (05) :813-824
[7]   Utilizing circulating tumor cells: challenges and pitfalls [J].
Attard, Gerhardt ;
de Bono, Johann S. .
CURRENT OPINION IN GENETICS & DEVELOPMENT, 2011, 21 (01) :50-58
[8]   Dealing with microscopic peritoneal metastases of epithelial ovarian cancer. A surgical challenge [J].
Azais, Henri ;
Estevez, Juan Pablo ;
Foucher, Perine ;
Kerbage, Yohan ;
Mordon, Serge ;
Collinet, Pierre .
SURGICAL ONCOLOGY-OXFORD, 2017, 26 (01) :46-52
[9]   Next Generation Sequencing of Tumor and Matched Plasma Samples: Identification of Somatic Variants in ctDNA From Ovarian Cancer Patients [J].
Barbosa, Ana ;
Pinto, Pedro ;
Peixoto, Ana ;
Guerra, Joana ;
Pinheiro, Manuela ;
Santos, Catarina ;
Pinto, Carla ;
Escudeiro, Carla ;
Bartosch, Carla ;
Santos, Rui ;
Brandao, Andreia ;
Silva, Joao ;
Teixeira, Manuel R. .
FRONTIERS IN ONCOLOGY, 2021, 11
[10]   Quality-adjusted time without symptoms of disease or toxicity and quality-adjusted progression-free survival with niraparib maintenance in first-line ovarian cancer in the PRIMA trial [J].
Barretina-Ginesta, Maria-Pilar ;
Monk, Bradley J. ;
Han, Sileny ;
Pothuri, Bhavana ;
Auranen, Annika ;
Chase, Dana M. ;
Lorusso, Domenica ;
Anderson, Charles ;
Abadie-Lacourtoisie, Sophie ;
Cloven, Noelle ;
Braicu, Elena, I ;
Amit, Amnon ;
Redondo, Andres ;
Shah, Ruchit ;
Kebede, Nehemiah ;
Hawkes, Carol ;
Gupta, Divya ;
Woodward, Tatia ;
O'Malley, David M. ;
Gonzalez-Martin, Antonio .
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2022, 14